{ "kind": "all", "value": "all", "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations", "filters": { "documentKinds": [], "sourceTypes": [], "orientations": [] }, "total": 319975, "page": 3611, "pageSize": 60, "pageCount": 5333, "rows": [ { "docId": "019de075-e1f8-726f-9315-81fdfad7abab", "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": "https://imgproxy.kitesheet.com/7tCYp-A0_DHkif5EWhvfVNF01HbNAuiAi2DU1oh6TD8/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9iMjMyNzViYzJlNjkwZWNmOTE3MTFmNWYxYzkyZmQzZC9wMDAxLmpwZw", "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/1", "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab", "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-1", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": "https://imgproxy.kitesheet.com/0VxupJe8_3g2vBXWRBVaAfgmiH4gmsRYzcGZgPWsJKA/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9iMjMyNzViYzJlNjkwZWNmOTE3MTFmNWYxYzkyZmQzZC9wMDAxLnBuZw", "thumbSrc": "https://imgproxy.kitesheet.com/hqU2iIgmgz9mK2makqFBPHO2ViAIPhUd1-b_-Sei7BU/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9iMjMyNzViYzJlNjkwZWNmOTE3MTFmNWYxYzkyZmQzZC9wMDAxLmpwZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/nzysKb0c1xOwP5dFFlBnBZDsXEzMxtO6ejmt2EKz5LI/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9iMjMyNzViYzJlNjkwZWNmOTE3MTFmNWYxYzkyZmQzZC9wMDAxLnBuZw" }, { "docId": "019de075-e1f8-726f-9315-81fdfad7abab", "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 2, "slideType": "appendix_disclosure", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/2", "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab", "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-2", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e1f8-726f-9315-81fdfad7abab", "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 3, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a horizontal bar chart to represent the development stage of each program.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/3", "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab", "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-3", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e1f8-726f-9315-81fdfad7abab", "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 4, "slideType": "product_demo", "function": "present_solution", "notes": "The slide uses a structured comparison layout to differentiate between individual programs and a combination strategy.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/4", "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab", "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-4", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e1f8-726f-9315-81fdfad7abab", "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 5, "slideType": "problem_statement", "function": "frame_problem", "notes": "The chart plots UC maintenance remission rates against maintenance dosing frequency, showing current standard-of-care drugs clustered at lower efficacy and higher frequency, while the 'Spyre Target' is positioned at higher efficacy and lower frequency.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/5", "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab", "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-5", "loopMatches": [ { "to": 6, "from": 5, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "b7091b28-a531-4677-b268-c8e3a5804fd9", "evidence": "The problem statement on page 5 sets up the need for improved treatment", "position": 0, "objective": "What are the consequences of not improving IBD treatment?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 5, "from": 5, "beatId": "8c6ed229-d96c-429b-bd2d-60c9ffc643e0", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "The document presents a clear problem statement on page 5", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e1f8-726f-9315-81fdfad7abab", "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 6, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a three-column layout to present distinct technological approaches.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/6", "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab", "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-6", "loopMatches": [ { "to": 6, "from": 5, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "b7091b28-a531-4677-b268-c8e3a5804fd9", "evidence": "The problem statement on page 5 sets up the need for improved treatment", "position": 0, "objective": "What are the consequences of not improving IBD treatment?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" }, { "to": 19, "from": 6, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "0f2e25ea-e3dc-4c15-9e23-1d88590fd563", "evidence": "The solution section presents a clear 'why' for Spyre's approach", "position": 1, "objective": "Why does Spyre's approach make sense?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 19, "from": 6, "beatId": "68c6fca4-e8f4-4ede-b0dc-880b8c41a146", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents a detailed solution, including SPY001 and SPY002, from pages 6 to 19", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e1f8-726f-9315-81fdfad7abab", "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 7, "slideType": "roadmap", "function": "plan_implementation", "notes": "The chart uses a horizontal bar representation to indicate progress through discovery and IND-enabling stages.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/7", "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab", "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-7", "loopMatches": [ { "to": 19, "from": 6, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "0f2e25ea-e3dc-4c15-9e23-1d88590fd563", "evidence": "The solution section presents a clear 'why' for Spyre's approach", "position": 1, "objective": "Why does Spyre's approach make sense?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 19, "from": 6, "beatId": "68c6fca4-e8f4-4ede-b0dc-880b8c41a146", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents a detailed solution, including SPY001 and SPY002, from pages 6 to 19", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e1f8-726f-9315-81fdfad7abab", "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 8, "slideType": "cover", "function": "front_matter", "notes": "The slide features a stylized antibody graphic overlaid on a dark blue/purple abstract background.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/8", "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab", "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-8", "loopMatches": [ { "to": 19, "from": 6, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "0f2e25ea-e3dc-4c15-9e23-1d88590fd563", "evidence": "The solution section presents a clear 'why' for Spyre's approach", "position": 1, "objective": "Why does Spyre's approach make sense?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 19, "from": 6, "beatId": "68c6fca4-e8f4-4ede-b0dc-880b8c41a146", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents a detailed solution, including SPY001 and SPY002, from pages 6 to 19", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e1f8-726f-9315-81fdfad7abab", "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 9, "slideType": "solution", "function": "present_solution", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/9", "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab", "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-9", "loopMatches": [ { "to": 19, "from": 6, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "0f2e25ea-e3dc-4c15-9e23-1d88590fd563", "evidence": "The solution section presents a clear 'why' for Spyre's approach", "position": 1, "objective": "Why does Spyre's approach make sense?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 19, "from": 6, "beatId": "68c6fca4-e8f4-4ede-b0dc-880b8c41a146", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents a detailed solution, including SPY001 and SPY002, from pages 6 to 19", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e1f8-726f-9315-81fdfad7abab", "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 10, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a structural biology visualization and two dose-response curves to establish bio-equivalence and differentiation.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/10", "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab", "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-10", "loopMatches": [ { "to": 19, "from": 6, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "0f2e25ea-e3dc-4c15-9e23-1d88590fd563", "evidence": "The solution section presents a clear 'why' for Spyre's approach", "position": 1, "objective": "Why does Spyre's approach make sense?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 19, "from": 6, "beatId": "68c6fca4-e8f4-4ede-b0dc-880b8c41a146", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents a detailed solution, including SPY001 and SPY002, from pages 6 to 19", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e1f8-726f-9315-81fdfad7abab", "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 11, "slideType": "traction", "function": "show_traction", "notes": "The slide uses two semi-logarithmic line charts to compare drug concentration decay over time.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/11", "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab", "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-11", "loopMatches": [ { "to": 19, "from": 6, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "0f2e25ea-e3dc-4c15-9e23-1d88590fd563", "evidence": "The solution section presents a clear 'why' for Spyre's approach", "position": 1, "objective": "Why does Spyre's approach make sense?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 19, "from": 6, "beatId": "68c6fca4-e8f4-4ede-b0dc-880b8c41a146", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents a detailed solution, including SPY001 and SPY002, from pages 6 to 19", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e1f8-726f-9315-81fdfad7abab", "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 12, "slideType": "key_takeaways", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/12", "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab", "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-12", "loopMatches": [ { "to": 19, "from": 6, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "0f2e25ea-e3dc-4c15-9e23-1d88590fd563", "evidence": "The solution section presents a clear 'why' for Spyre's approach", "position": 1, "objective": "Why does Spyre's approach make sense?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 19, "from": 6, "beatId": "68c6fca4-e8f4-4ede-b0dc-880b8c41a146", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents a detailed solution, including SPY001 and SPY002, from pages 6 to 19", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e1f8-726f-9315-81fdfad7abab", "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 13, "slideType": "appendix_methodology", "function": "present_framework", "notes": "The slide uses a stepped process diagram to illustrate dose escalation cohorts.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/13", "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab", "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-13", "loopMatches": [ { "to": 19, "from": 6, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "0f2e25ea-e3dc-4c15-9e23-1d88590fd563", "evidence": "The solution section presents a clear 'why' for Spyre's approach", "position": 1, "objective": "Why does Spyre's approach make sense?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 19, "from": 6, "beatId": "68c6fca4-e8f4-4ede-b0dc-880b8c41a146", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents a detailed solution, including SPY001 and SPY002, from pages 6 to 19", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e1f8-726f-9315-81fdfad7abab", "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 14, "slideType": "traction", "function": "analyze_data", "notes": "The slide uses a comparative bar chart approach to justify the human half-life prediction based on NHP data.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/14", "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab", "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-14", "loopMatches": [ { "to": 19, "from": 6, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "0f2e25ea-e3dc-4c15-9e23-1d88590fd563", "evidence": "The solution section presents a clear 'why' for Spyre's approach", "position": 1, "objective": "Why does Spyre's approach make sense?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 19, "from": 6, "beatId": "68c6fca4-e8f4-4ede-b0dc-880b8c41a146", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents a detailed solution, including SPY001 and SPY002, from pages 6 to 19", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e1f8-726f-9315-81fdfad7abab", "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 15, "slideType": "comparison_table", "function": "compare_peers", "notes": "Uses icon-based visualization to represent injection frequency.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/15", "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab", "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-15", "loopMatches": [ { "to": 19, "from": 6, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "0f2e25ea-e3dc-4c15-9e23-1d88590fd563", "evidence": "The solution section presents a clear 'why' for Spyre's approach", "position": 1, "objective": "Why does Spyre's approach make sense?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 19, "from": 6, "beatId": "68c6fca4-e8f4-4ede-b0dc-880b8c41a146", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents a detailed solution, including SPY001 and SPY002, from pages 6 to 19", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e1f8-726f-9315-81fdfad7abab", "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 16, "slideType": "appendix_data", "function": "analyze_data", "notes": "The slide uses a combination of a pharmacokinetic simulation line chart and a bar chart showing clinical remission rates by exposure quartile.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/16", "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab", "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-16", "loopMatches": [ { "to": 19, "from": 6, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "0f2e25ea-e3dc-4c15-9e23-1d88590fd563", "evidence": "The solution section presents a clear 'why' for Spyre's approach", "position": 1, "objective": "Why does Spyre's approach make sense?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 19, "from": 6, "beatId": "68c6fca4-e8f4-4ede-b0dc-880b8c41a146", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents a detailed solution, including SPY001 and SPY002, from pages 6 to 19", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e1f8-726f-9315-81fdfad7abab", "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 17, "slideType": "comparison_table", "function": "compare_peers", "notes": "The slide uses a timeline-like visual to compare dosing schedules at weeks 0, 2, and 6.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/17", "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab", "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-17", "loopMatches": [ { "to": 19, "from": 6, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "0f2e25ea-e3dc-4c15-9e23-1d88590fd563", "evidence": "The solution section presents a clear 'why' for Spyre's approach", "position": 1, "objective": "Why does Spyre's approach make sense?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 19, "from": 6, "beatId": "68c6fca4-e8f4-4ede-b0dc-880b8c41a146", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents a detailed solution, including SPY001 and SPY002, from pages 6 to 19", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e1f8-726f-9315-81fdfad7abab", "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 18, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a comparative table for safety metrics and a bar chart for ADA rates to establish clinical equivalence/safety.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/18", "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab", "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-18", "loopMatches": [ { "to": 19, "from": 6, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "0f2e25ea-e3dc-4c15-9e23-1d88590fd563", "evidence": "The solution section presents a clear 'why' for Spyre's approach", "position": 1, "objective": "Why does Spyre's approach make sense?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 19, "from": 6, "beatId": "68c6fca4-e8f4-4ede-b0dc-880b8c41a146", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents a detailed solution, including SPY001 and SPY002, from pages 6 to 19", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e1f8-726f-9315-81fdfad7abab", "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 19, "slideType": "executive_summary", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/19", "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab", "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-19", "loopMatches": [ { "to": 19, "from": 6, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "0f2e25ea-e3dc-4c15-9e23-1d88590fd563", "evidence": "The solution section presents a clear 'why' for Spyre's approach", "position": 1, "objective": "Why does Spyre's approach make sense?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 19, "from": 6, "beatId": "68c6fca4-e8f4-4ede-b0dc-880b8c41a146", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The document presents a detailed solution, including SPY001 and SPY002, from pages 6 to 19", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e1f8-726f-9315-81fdfad7abab", "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 20, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/20", "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab", "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-20", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e1f8-726f-9315-81fdfad7abab", "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 21, "slideType": "solution", "function": "present_solution", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/21", "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab", "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-21", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e1f8-726f-9315-81fdfad7abab", "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 22, "slideType": "solution", "function": "present_solution", "notes": "The funnel diagram illustrates the selection criteria: Monomer/Trimer binder -> Picomolar potency -> Extended half-life.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/22", "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab", "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-22", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e1f8-726f-9315-81fdfad7abab", "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 23, "slideType": "traction", "function": "show_traction", "notes": "The slide uses two distinct chart types to demonstrate potency (dose-response curve) and diversity (scatter plot of IC50 vs Relative DcR3/DR3 Blocking).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/23", "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab", "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-23", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e1f8-726f-9315-81fdfad7abab", "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 24, "slideType": "competitive_analysis", "function": "compare_peers", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/24", "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab", "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-24", "loopMatches": [], "arcBeatMatches": [ { "to": 24, "from": 24, "beatId": "0d553f9e-bdc3-4321-9290-0329c7071225", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Competition", "beatSlug": "sequoia-pitch-competition", "evidence": "The document presents a competitive analysis on page 24", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e1f8-726f-9315-81fdfad7abab", "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 25, "slideType": "key_takeaways", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/25", "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab", "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-25", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e1f8-726f-9315-81fdfad7abab", "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 26, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/26", "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab", "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-26", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e1f8-726f-9315-81fdfad7abab", "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 27, "slideType": "unfair_advantage", "function": "present_solution", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/27", "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab", "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-27", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e1f8-726f-9315-81fdfad7abab", "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 28, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a biological process diagram to illustrate the mechanism of action for three distinct therapeutic assets.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/28", "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab", "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-28", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e1f8-726f-9315-81fdfad7abab", "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 29, "slideType": "comparison_table", "function": "compare_peers", "notes": "The slide uses a stacked bar chart to visualize the additive clinical remission rates, noting a 22% delta between the individual components and the combination.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/29", "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab", "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-29", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e1f8-726f-9315-81fdfad7abab", "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 30, "slideType": "comparison_table", "function": "compare_peers", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/30", "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab", "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-30", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e1f8-726f-9315-81fdfad7abab", "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 31, "slideType": "key_takeaways", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/31", "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab", "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-31", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e1f8-726f-9315-81fdfad7abab", "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 32, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/32", "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab", "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-32", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e1f8-726f-9315-81fdfad7abab", "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 33, "slideType": "team_bio", "function": "other", "notes": "The slide includes a section for Management team and Board of Directors with headshots and titles, plus a logo grid at the bottom.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/33", "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab", "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-33", "loopMatches": [], "arcBeatMatches": [ { "to": 33, "from": 33, "beatId": "36d78305-5dbf-4639-888e-af1ef6ade8b1", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Team", "beatSlug": "sequoia-pitch-team", "evidence": "The document presents a team section on page 33", "position": 4, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e1f8-726f-9315-81fdfad7abab", "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 34, "slideType": "traction", "function": "plan_implementation", "notes": "The slide uses a timeline-like structure to map clinical catalysts against expected timeframes.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/34", "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab", "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-34", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e1f8-726f-9315-81fdfad7abab", "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 35, "slideType": "closing_ask", "function": "state_next_steps", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/35", "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab", "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-35", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e1f8-726f-9315-81fdfad7abab", "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 36, "slideType": "other", "function": "summarize", "notes": "The slide details a corporate M&A event and subsequent private placement financing.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/36", "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab", "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-36", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e1f8-726f-9315-81fdfad7abab", "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 37, "slideType": "appendix_data", "function": "analyze_data", "notes": "Includes a footnote regarding a 1-for-25 reverse stock split effective September 8, 2023.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/37", "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab", "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-37", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e109-770f-8f32-3054686041b6", "docSlug": "9819f3512e565b918c6cfc8e3688cfb2", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 21, "slideType": "solution", "function": "present_solution", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/21", "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6", "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-21", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e109-770f-8f32-3054686041b6", "docSlug": "9819f3512e565b918c6cfc8e3688cfb2", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 22, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a funnel diagram to illustrate the selection process from initial discovery sets to final candidate properties.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/22", "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6", "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-22", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e109-770f-8f32-3054686041b6", "docSlug": "9819f3512e565b918c6cfc8e3688cfb2", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 23, "slideType": "solution", "function": "present_solution", "notes": "The slide uses two distinct chart types: a scatter plot for binding affinity and a dose-response curve for functional inhibition.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/23", "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6", "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-23", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e109-770f-8f32-3054686041b6", "docSlug": "9819f3512e565b918c6cfc8e3688cfb2", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 24, "slideType": "competitive_analysis", "function": "compare_peers", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/24", "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6", "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-24", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e109-770f-8f32-3054686041b6", "docSlug": "9819f3512e565b918c6cfc8e3688cfb2", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 25, "slideType": "timeline", "function": "cite_precedent", "notes": "The slide uses a timeline to frame recent industry activity as validation for the company's asset.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/25", "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6", "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-25", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e109-770f-8f32-3054686041b6", "docSlug": "9819f3512e565b918c6cfc8e3688cfb2", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 26, "slideType": "executive_summary", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/26", "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6", "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-26", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e109-770f-8f32-3054686041b6", "docSlug": "9819f3512e565b918c6cfc8e3688cfb2", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 27, "slideType": "section_divider", "function": "transition", "notes": "The graphic overlays on the photo are stylized representations of antibodies, suggesting a biotech/pharma context.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/27", "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6", "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-27", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e109-770f-8f32-3054686041b6", "docSlug": "9819f3512e565b918c6cfc8e3688cfb2", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 28, "slideType": "unfair_advantage", "function": "present_solution", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/28", "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6", "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-28", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e109-770f-8f32-3054686041b6", "docSlug": "9819f3512e565b918c6cfc8e3688cfb2", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 29, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a biological process diagram to map drug targets to specific cellular mechanisms (T-cell trafficking, Colonic Fibrosis, Inflammatory cascade, Th17 maturation).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/29", "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6", "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-29", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e109-770f-8f32-3054686041b6", "docSlug": "9819f3512e565b918c6cfc8e3688cfb2", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 30, "slideType": "comparison_table", "function": "compare_peers", "notes": "The chart uses a stacked bar to visualize the additive nature of the combination therapy compared to the individual components.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/30", "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6", "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-30", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e109-770f-8f32-3054686041b6", "docSlug": "9819f3512e565b918c6cfc8e3688cfb2", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 31, "slideType": "comparison_table", "function": "compare_peers", "notes": "The table highlights that Spyre's products possess specific safety and efficacy features (no black box warning, dual mechanism, extended half-life) that the competitor lacks.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/31", "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6", "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-31", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e109-770f-8f32-3054686041b6", "docSlug": "9819f3512e565b918c6cfc8e3688cfb2", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 32, "slideType": "key_takeaways", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/32", "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6", "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-32", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e109-770f-8f32-3054686041b6", "docSlug": "9819f3512e565b918c6cfc8e3688cfb2", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 33, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/33", "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6", "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-33", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e109-770f-8f32-3054686041b6", "docSlug": "9819f3512e565b918c6cfc8e3688cfb2", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 34, "slideType": "team_bio", "function": "other", "notes": "The slide includes a section for Management team and Board of Directors with headshots and titles, followed by a logo grid of affiliated organizations.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/34", "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6", "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-34", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e109-770f-8f32-3054686041b6", "docSlug": "9819f3512e565b918c6cfc8e3688cfb2", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 35, "slideType": "traction", "function": "show_traction", "notes": "The slide combines financial runway with a clinical development timeline.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/35", "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6", "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-35", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e109-770f-8f32-3054686041b6", "docSlug": "9819f3512e565b918c6cfc8e3688cfb2", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 36, "slideType": "closing_ask", "function": "state_next_steps", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/36", "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6", "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-36", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e109-770f-8f32-3054686041b6", "docSlug": "9819f3512e565b918c6cfc8e3688cfb2", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 37, "slideType": "other", "function": "other", "notes": "This slide outlines the M&A transaction details including a $210M private placement.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/37", "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6", "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-37", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e109-770f-8f32-3054686041b6", "docSlug": "9819f3512e565b918c6cfc8e3688cfb2", "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides", "authorId": "aeglea-biotherapeutics", "authorName": "Spyre Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 38, "slideType": "appendix_data", "function": "analyze_data", "notes": "Includes a footnote regarding a 1-for-25 reverse stock split effective September 8, 2023.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/38", "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6", "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-38", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e29f-7298-83f4-f399e710dc49", "docSlug": "23480e67a083cbde563694d24fd9cdc8", "documentTitle": "AKT Pictures | Other Presentation Deck | 17 slides", "authorId": "akt-pictures", "authorName": null, "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": "The logo features negative space silhouettes of a person and a dog within the letters.", "imagePath": "https://imgproxy.kitesheet.com/RNRuXy8vfQWeTdj6-QxrjvUddku48NxtHzWKuEioRDI/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8yMzQ4MGU2N2EwODNjYmRlNTYzNjk0ZDI0ZmQ5Y2RjOC9wMDAxLmpwZw", "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e29f-7298-83f4-f399e710dc49/1", "deckHref": "/decks/019de075-e29f-7298-83f4-f399e710dc49", "deckAnchorHref": "/decks/019de075-e29f-7298-83f4-f399e710dc49#slide-1", "loopMatches": [], "arcBeatMatches": [ { "to": 2, "from": 1, "beatId": "a251dbee-4536-4069-9442-726ec0659c7c", "arcName": "The Sparkline", "arcSlug": "sparkline", "beatName": "What Is", "beatSlug": "sparkline-what-is-1", "evidence": "The cover slides introduce the theme.", "position": 0, "confidence": 0.8, "parentBeatName": "Setup", "parentBeatSlug": "setup" } ], "imagePathAlt": "https://imgproxy.kitesheet.com/glPpRii3ZubzjFiZpG8ge5U6pRqengHwwrnflb5S89Y/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8yMzQ4MGU2N2EwODNjYmRlNTYzNjk0ZDI0ZmQ5Y2RjOC9wMDAxLnBuZw", "thumbSrc": "https://imgproxy.kitesheet.com/IDriIlqzdxu3xeAzYAtnVhD-Js8v9M152i1da9KRYZg/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8yMzQ4MGU2N2EwODNjYmRlNTYzNjk0ZDI0ZmQ5Y2RjOC9wMDAxLmpwZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/ddUDPDw6sTj511iMQ0rTGc4HsOkZTRv2EMmh78jtW0k/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8yMzQ4MGU2N2EwODNjYmRlNTYzNjk0ZDI0ZmQ5Y2RjOC9wMDAxLnBuZw" }, { "docId": "019de075-e29f-7298-83f4-f399e710dc49", "docSlug": "23480e67a083cbde563694d24fd9cdc8", "documentTitle": "AKT Pictures | Other Presentation Deck | 17 slides", "authorId": "akt-pictures", "authorName": null, "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 2, "slideType": "cover", "function": "front_matter", "notes": "The visual uses a silhouette of a man with a dog's shadow, reinforcing the premise.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e29f-7298-83f4-f399e710dc49/2", "deckHref": "/decks/019de075-e29f-7298-83f4-f399e710dc49", "deckAnchorHref": "/decks/019de075-e29f-7298-83f4-f399e710dc49#slide-2", "loopMatches": [], "arcBeatMatches": [ { "to": 2, "from": 1, "beatId": "a251dbee-4536-4069-9442-726ec0659c7c", "arcName": "The Sparkline", "arcSlug": "sparkline", "beatName": "What Is", "beatSlug": "sparkline-what-is-1", "evidence": "The cover slides introduce the theme.", "position": 0, "confidence": 0.8, "parentBeatName": "Setup", "parentBeatSlug": "setup" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e29f-7298-83f4-f399e710dc49", "docSlug": "23480e67a083cbde563694d24fd9cdc8", "documentTitle": "AKT Pictures | Other Presentation Deck | 17 slides", "authorId": "akt-pictures", "authorName": null, "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 3, "slideType": "ceo_quote", "function": "establish_context", "notes": "The slide features a personal narrative and a photo of the director on set.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e29f-7298-83f4-f399e710dc49/3", "deckHref": "/decks/019de075-e29f-7298-83f4-f399e710dc49", "deckAnchorHref": "/decks/019de075-e29f-7298-83f4-f399e710dc49#slide-3", "loopMatches": [ { "to": 5, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "12015b19-bbe1-4e9c-a55f-80ebeebf48d4", "evidence": "The director's statement and synopsis provide insight into the project's 'why'.", "position": 0, "objective": "Understand the project's purpose and values.", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.6, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 5, "from": 3, "beatId": "bb06295e-2355-467c-8334-4c0bec5b918a", "arcName": "The Sparkline", "arcSlug": "sparkline", "beatName": "Ordinary World", "beatSlug": "heros-journey-ordinary-world", "evidence": "The director's statement and synopsis provide context.", "position": 1, "confidence": 0.8, "parentBeatName": "Setup", "parentBeatSlug": "setup" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e29f-7298-83f4-f399e710dc49", "docSlug": "23480e67a083cbde563694d24fd9cdc8", "documentTitle": "AKT Pictures | Other Presentation Deck | 17 slides", "authorId": "akt-pictures", "authorName": null, "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 4, "slideType": "other", "function": "other", "notes": "The slide uses a movie still (likely from 'Clueless') to illustrate the narrative.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e29f-7298-83f4-f399e710dc49/4", "deckHref": "/decks/019de075-e29f-7298-83f4-f399e710dc49", "deckAnchorHref": "/decks/019de075-e29f-7298-83f4-f399e710dc49#slide-4", "loopMatches": [ { "to": 5, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "12015b19-bbe1-4e9c-a55f-80ebeebf48d4", "evidence": "The director's statement and synopsis provide insight into the project's 'why'.", "position": 0, "objective": "Understand the project's purpose and values.", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.6, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 5, "from": 3, "beatId": "bb06295e-2355-467c-8334-4c0bec5b918a", "arcName": "The Sparkline", "arcSlug": "sparkline", "beatName": "Ordinary World", "beatSlug": "heros-journey-ordinary-world", "evidence": "The director's statement and synopsis provide context.", "position": 1, "confidence": 0.8, "parentBeatName": "Setup", "parentBeatSlug": "setup" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-e29f-7298-83f4-f399e710dc49", "docSlug": "23480e67a083cbde563694d24fd9cdc8", "documentTitle": "AKT Pictures | Other Presentation Deck | 17 slides", "authorId": "akt-pictures", "authorName": null, "documentKindSlug": "deck", "documentKindLabel": "Deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 5, "slideType": "other", "function": "illustrate_case", "notes": "The slide uses a split-image layout to define the film's visual world-building.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-e29f-7298-83f4-f399e710dc49/5", "deckHref": "/decks/019de075-e29f-7298-83f4-f399e710dc49", "deckAnchorHref": "/decks/019de075-e29f-7298-83f4-f399e710dc49#slide-5", "loopMatches": [ { "to": 5, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "12015b19-bbe1-4e9c-a55f-80ebeebf48d4", "evidence": "The director's statement and synopsis provide insight into the project's 'why'.", "position": 0, "objective": "Understand the project's purpose and values.", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.6, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 5, "from": 3, "beatId": "bb06295e-2355-467c-8334-4c0bec5b918a", "arcName": "The Sparkline", "arcSlug": "sparkline", "beatName": "Ordinary World", "beatSlug": "heros-journey-ordinary-world", "evidence": "The director's statement and synopsis provide context.", "position": 1, "confidence": 0.8, "parentBeatName": "Setup", "parentBeatSlug": "setup" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true } ] }